The Medical Letter on Drugs and Therapeutics
A New Subcutaneous Immune Globulin (HyQvia) for Primary Immunodeficiency
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Immune globulin (IgG) has been available for administration intravenously once every 3-4 weeks or subcutaneously once daily, once weekly, or every 2 weeks for treatment of primary immunodeficiencies. Now the FDA has approved human immune globulin 10% with recombinant human hyaluronidase (HyQvia – Baxter) for subcutaneous administration only every 3-4 weeks in adults with these disorders. The IgG component of HyQvia is identical to Gammagard Liquid, which was approved in 2005 for IV administration and in 2011 for SC administration.

PRIMARY IMMUNODEFICIENCY — Primary immunodeficiencies include common variable immunodeficiency (CVID), X-linked or congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.1 These disorders are usually congenital or develop in early childhood, but may also develop later ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A New Subcutaneous Immune Globulin (HyQvia) for Primary Immunodeficiency
Article code: 1476b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian